Physiomics plc
("Physiomics") or ("the Company")
Physiomics to present first validation of its Virtual Tumour Clinical platform at Annual Meeting for American Association for Cancer Research ("AACR")
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the AACR Annual Meeting 2014, taking place at the San Diego Convention Center, San Diego, CA on 5-9 April 2014. Dr Eric Fernandez will present on the first validation of the Virtual Tumour Clinical platform.
We have now extended and adapted our preclinical model to predict efficacy in the clinic, thus creating the "Virtual Tumour Clinical". This is the culmination of a 6 month study collaborating with the National Cancer Institute (NIH, Bethesda, MD). Here we show a comparative study of the preclinical Virtual Tumour and of the Virtual Tumour Clinical version for prostate combination data. The results show how our new model can translate the effect of the drug combination from the preclinical situation to the clinic.
Now that the technology has been validated in prostate cancer, the next step will be to apply Virtual Tumour Clinical to other indications. In parallel, discussions are ongoing with large pharmaceutical companies to initiate the first project to proactively use Virtual Tumour Clinical to predict outcomes for a novel pipeline drug.
The abstract ("Translational modeling of docetaxel-thalidomide combination treatment in metastatic, castrate-resistant prostate cancer: predicting clinical response using preclinical data", No 366) will be presented in the "Cancer Systems Biology" poster session, scheduled 1:00 PM - 5:00 PM, 06 April 2014.
More information about the conference may be found at:
http://www.aacr.org/home/scientists/meetings--workshops/aacr-annual-meeting-2014.aspx
Dr Mark Chadwick, CEO of Physiomics, commented:
"We are extremely pleased to present this first validation of our flagship Virtual Tumour Clinical technology. The results of this collaboration give us great encouragement that we will be able to adapt the platform to a number of different tumour types in a clinical setting. In particular, we expect to present further validation results made in collaboration with Oxford University in the near future. We are also currently in discussions with the first large pharma company who will take on and help us further develop Virtual Tumour Clinical."
Enquiries:
Physiomics plc
Dr Mark Chadwick, CEO
+44 (0)1865 784 980
WH Ireland Limited (broker/nomad)
Katy Mitchell
+44 (0) 161 832 2174
About Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.
Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com
SystemCell® is a registered trademark of Physiomics plc
1Tufts Centre Impact Report 2002
